Press release: Launch of a Phase I clinical Trial of an HIV vaccine
Professor Tetsuro Matano, Department of AIDS Vaccine Decelopment:
The New York-based International AIDS Vaccine Initiative (IAVI) and the Japan-based biotech DNAVEC Corporation announced the start of a Phase I clinical trial of an HIV vaccine candidate using Sendai virus (SeV) vector at three locations including England and Rwanda. The SeV vector AIDS vaccine system has been developed by our research group.